Baidu
map

Stroke:有卒中危险因素的人群行抗血栓治疗,可改善卒中后预后

2016-07-26 phylis 译 MedSci原创

背景:抗凝治疗是脑卒中一级和二级预防治疗的中流砥柱,急性事件前使用可能与更好预后相关。方法:使用“跟随卒中指南”中的数据,受试者为2011年10月至2014年3月间美国1661家医院50万急性缺血性卒中患者(N = 540 993)。研究者研究了应用抗凝药物和临床预后的校正和未校正相关性。结果:卒中前,250 104(46%)例脑卒中患者未接受任何抗血栓治疗;其中约三分之一的患者有以前血管显示的记

背景:抗凝治疗是脑卒中一级和二级预防治疗的中流砥柱,急性事件前使用可能与更好预后相关。

方法:使用“跟随卒中指南”中的数据,受试者为2011年10月至2014年3月间美国1661家医院50万急性缺血性卒中患者(N = 540 993)。研究者研究了应用抗凝药物和临床预后的校正和未校正相关性。

结果:卒中前,250 104(46%)例脑卒中患者未接受任何抗血栓治疗;其中约三分之一的患者有以前血管显示的记录。控制临床和医院的因素后,患者卒中前接受抗血栓治疗的预后好于未进行抗血栓治疗的患者。有比那些没有更好的结果,不管以前的血管显示是否存在:住院死亡率的校正OR(95%CI)为0.82(0.80-0.84),出院回家的OR值为1.18(1.16-1.19),出院时能独立行走的OR为1.15(1.13-1.16),出院时mRS评分为0或1的OR值为1.15(1.12-1.17)。

结论:先前抗血栓治疗与急性缺血性卒中临床预后的改善独立相关。确保合适的病人使用抗血栓治疗与卒中良好预后相关。

原始出处:

Myint PK, Hellkamp AS,et al. Prior Antithrombotic Use Is Associated With Favorable Mortality and Functional Outcomes in Acute Ischemic Stroke. Stroke. 2016 Jul 19.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671256, encodeId=465c16e125633, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Nov 06 11:47:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145339, encodeId=5fec145339f5, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:15:06 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385509, encodeId=af1f138550928, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Jul 27 20:47:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574094, encodeId=8dad15e4094a0, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Jul 27 20:47:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671256, encodeId=465c16e125633, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Nov 06 11:47:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145339, encodeId=5fec145339f5, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:15:06 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385509, encodeId=af1f138550928, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Jul 27 20:47:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574094, encodeId=8dad15e4094a0, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Jul 27 20:47:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
    2016-10-11 ylzr123

    赞了,认真探究、学习。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1671256, encodeId=465c16e125633, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Nov 06 11:47:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145339, encodeId=5fec145339f5, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:15:06 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385509, encodeId=af1f138550928, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Jul 27 20:47:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574094, encodeId=8dad15e4094a0, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Jul 27 20:47:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671256, encodeId=465c16e125633, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Sun Nov 06 11:47:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145339, encodeId=5fec145339f5, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:15:06 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385509, encodeId=af1f138550928, content=<a href='/topic/show?id=1ea455e6064' target=_blank style='color:#2F92EE;'>#抗血栓治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55760, encryptionId=1ea455e6064, topicName=抗血栓治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Wed Jul 27 20:47:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574094, encodeId=8dad15e4094a0, content=<a href='/topic/show?id=ee4955e5730' target=_blank style='color:#2F92EE;'>#抗血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55757, encryptionId=ee4955e5730, topicName=抗血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a26516008049, createdName=gwc388, createdTime=Wed Jul 27 20:47:00 CST 2016, time=2016-07-27, status=1, ipAttribution=)]
    2016-07-27 gwc388

相关资讯

Stroke:介入治疗大血管闭塞性卒中是有效的(独立于静脉溶栓)

背景:在过去的十年,紧急大血管闭塞的血管内介入治疗(ELVO)发展迅速。是否静脉溶栓(IVT)预处理对ELVO患者功能预后有显著的影响仍不清楚。方法:研究对所有评估血管内治疗(ET)对急性缺血性卒中的疗效的随机对照试验,进行了系统的综述和荟萃分析。研究者按照IVT预治疗进行分层,进行的混合效应亚组分析报告,对ET(与标准治疗)与3功能结果的相关性的OR值。结果:纳入六项随机对照试验,包括1916

Stroke:收缩压与血管性痴呆的风险呈正相关

背景:血管性痴呆是第二大常见痴呆形式,但血压(BP)和血管性痴呆发生的风险特定年龄的相关性的可靠证据是有限的,一些研究报告在年龄较大的负面联想。方法:从电子初级保健健康档案(英国临床实践研究数据库)中识别无已知的心血管疾病和老年痴呆症428万人。研究者将BP和诊断血管性痴呆的时间联系起来。研究者在短暂性脑缺血发作和卒中(牛津血管研究)中进行潜在性的记录,探讨血压和老年痴呆症之间的关联。结果:随访时

Stroke:临床量表不能准确识别大动脉闭塞性卒中

背景:临床评分是否可以帮助识别急性大动脉闭塞的缺血性卒中患者,改善治疗的分类是有争议的。研究者旨在确定公布的临床评分预测大动脉闭塞的准确性。方法:研究者评估了13个临床评分预测急性缺血性脑卒中患者大动脉闭塞的性能,这些患者发病6小时内进行临床检查和磁共振或CT血管造影。当无界值点时,研究者使用界值最大化的增加研究队列敏感性和特异性的总和。研究者还决定,对每一个评分,一个假阴性率≤10%与界值点相关

JAHA:年轻人要警惕卒中和TIA

背景:研究报告称,年轻成人缺血性脑卒中的发病率高于50岁至55岁的成年人。对其他亚型的卒中和短暂性脑缺血发作(TIA)的时间趋势信息是不足的。本研究的目的是探讨年龄15岁至30岁TIA和卒中住院率的变化趋势,包括性别和亚型特异性趋势。方法和结果:从丹麦国家病人登记记录中,研究者确定在丹麦所有1994-2012年住院的首次卒中和TIA患者(年龄15-30岁)。采用泊松回归估计估计年度百分比变化率(E

2009APSS建议——卒中二级预防发布

2009年2月,阿尔伯塔省卒中策略(APSS,Alberta Provincial Stroke Strategy))公布了卒中二级预防建议,主要为卒中二级预防服务提供指南,为临床管理提供最佳实践指导。获取全文:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载)

2010APSS建议——急性卒中急诊管理发布

2010年1月,阿尔伯塔省卒中策略(APSS)公布了急性卒中急诊管理建议,该建议主要内容涉及神经血管影像,神经生命体征,血糖,急性期溶栓治疗,ITA和小卒中的紧急处理,急性期阿司匹林治疗,吞咽障碍筛查和评估,蛛网膜下腔出血和脑出血的处理,卒中康复初步评估等内容。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载)

Baidu
map
Baidu
map
Baidu
map